Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
Standard pomalidomide dosing (4 mg/day for 21 of 28 days) achieved the most robust pharmacokinetic (PK) and pharmacodynamic (PD) effects. Daily dosing with pomalidomide 2 mg is a safe alternative for patients at risk of toxicity; alternate-day dosing was less effective.
Authors
- Mark‐David Levin (ORCID: https://orcid.org/0000-0003-2139-3547)
- David G. J. Cucchi (ORCID: https://orcid.org/0000-0001-6706-5464)
- Maarten R. Seefat (ORCID: https://orcid.org/0000-0002-0824-0354)
- Febe Smits (ORCID: https://orcid.org/0000-0002-5017-9550)
- Nazik Durdu-Rayman
- Rosa Rentenaar (ORCID: https://orcid.org/0009-0008-3317-437X)
- Ron A. A. Mathôt (ORCID: https://orcid.org/0000-0001-8401-0879)
- Maryka Quik
- Niels W.C.J. van de Donk (ORCID: https://orcid.org/0000-0002-7445-2603)
- Panagiota Tzortzi
- Ellen van der Spek
- Koen de Heer (ORCID: https://orcid.org/0000-0003-4655-6007)
- Marise R. Heerma van Voss (ORCID: https://orcid.org/0000-0001-8368-9859)
- Charlotte L.B.M. Korst (ORCID: https://orcid.org/0009-0005-0191-4343)
- Kevin Groen (ORCID: https://orcid.org/0000-0001-6352-1346)
- Tuna Mutis (ORCID: https://orcid.org/0000-0002-5557-7187)
- Sonja Zweegman (ORCID: https://orcid.org/0000-0002-5011-1820)
- Ruth Wester
- Catherine O’Neill (ORCID: https://orcid.org/0000-0002-5456-9396)
- Imke H. Bartelink (ORCID: https://orcid.org/0000-0001-9602-3407)
- B. De Valk
- Ludolf G. Boven
Institutions
- Sint Franciscus Gasthuis (NL)
- Albert Schweitzer Ziekenhuis (NL)
- Spaarne Ziekenhuis (NL)
- Amsterdam Neuroscience (NL)
- Flevoziekenhuis (NL)
- Haga Hospital (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
- Rijnstate Hospital (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1111/bjh.70239
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00